Paricalcitol is FDA-approved for which of the following condition(s):
**Core Concept**
Paricalcitol is a vitamin D analogue that acts as a selective agonist of the vitamin D receptor, mimicking the effects of calcitriol, the active form of vitamin D. It is used to treat secondary hyperparathyroidism in patients with chronic kidney disease.
**Why the Correct Answer is Right**
Paricalcitol works by binding to the vitamin D receptor, which then regulates the expression of genes involved in mineral ion homeostasis. This leads to a decrease in parathyroid hormone (PTH) levels, which is elevated in secondary hyperparathyroidism. The reduction in PTH levels helps to slow the progression of renal osteodystrophy and hyperphosphatemia. Paricalcitol's selective action on the vitamin D receptor also reduces the risk of hypercalcemia, a common side effect of calcitriol therapy.
**Why Each Wrong Option is Incorrect**
**Option A:** While paricalcitol is used to treat secondary hyperparathyroidism, it is not approved for the treatment of primary hyperparathyroidism, which is a different condition characterized by a parathyroid gland tumor or hyperplasia.
**Option B:** Paricalcitol is not approved for the treatment of osteoporosis, although it may have some beneficial effects on bone density in patients with chronic kidney disease.
**Option C:** Paricalcitol is not approved for the treatment of vitamin D deficiency, as it is a vitamin D analogue that is used to treat secondary hyperparathyroidism, not vitamin D deficiency.
**Clinical Pearl / High-Yield Fact**
Paricalcitol is a useful alternative to calcitriol in patients with chronic kidney disease, as it has a more selective action on the vitamin D receptor and may reduce the risk of hypercalcemia.
**Correct Answer: C. Secondary hyperparathyroidism in patients with chronic kidney disease.**